1P-BOL-148

1P-BOL-148

Clinical data
Other names	1-Propionyl-2-bromo-LSD; SYN-L-017
Identifiers
IUPAC name (6aR,9R)-5-bromo-N,N-diethyl-7-methyl-4-propanoyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
PubChem CID	169001441
Chemical and physical data
Formula	C23H28BrN3O2
Molar mass	458.400 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCC(=O)N1C2=CC=CC3=C2C(=C1Br)C[C@@H]4C3=C[C@H](CN4C)C(=O)N(CC)CC
InChI InChI=1S/C23H28BrN3O2/c1-5-20(28)27-18-10-8-9-15-16-11-14(23(29)26(6-2)7-3)13-25(4)19(16)12-17(21(15)18)22(27)24/h8-11,14,19H,5-7,12-13H2,1-4H3/t14-,19-/m1/s1 Key:PLXWJCJZSCKGNW-AUUYWEPGSA-N

1P-BOL-148, also known as 1-propionyl-2-bromo-LSD or as SYN-L-017, is an analogue of LSD which acts as a prodrug for 2-bromo-LSD (BOL-148). It does not have hallucinogenic effects, but is claimed to be potentially useful for the treatment of cluster headaches, ^[1] and as an antidepressant. ^[2]

See also

• Substituted lysergamide
• MBL-61 (1-methyl-2-bromo-LSD)
• 1-Methyl-2-iodo-LSD (MIL)
• 1P-LSD

References

1. WO 2024/028495,Stratford A, Williamson JP,"Prodrugs of Substituted Ergolines",published 8 February 2024, assigned to Synex Holdings BV 
2. WO 2023/141636,Duncton M, Clark S,"Prodrugs of 2-Bromo-LSD (2-Bromolysergic acid diethylamide)",published 27 July 2023, assigned to Terran Biosciences Inc.